Explore the available PrEP medication options, including daily oral pills and long-acting injections. Learn about their mechanisms, efficacy, and key considerations.

PrEP Medication Options: A Comprehensive Overview

Pre-Exposure Prophylaxis, commonly known as PrEP, is a highly effective HIV prevention method. It involves taking specific medications before potential exposure to HIV to reduce the risk of infection. Understanding the various PrEP medication options available is crucial for individuals considering this preventative strategy. This overview provides insights into the different forms of PrEP, their mechanisms, and important factors to consider.

1. Understanding PrEP and Its Efficacy

PrEP works by preventing the HIV virus from establishing a permanent infection in the body. When taken as prescribed, PrEP medications can reduce the risk of getting HIV from sexual activity by about 99% and from injection drug use by at least 74%. It is important to remember that PrEP is one component of a comprehensive HIV prevention strategy and does not protect against other sexually transmitted infections (STIs).

2. Oral PrEP: Daily Pill Options

Currently, two primary oral PrEP medications are approved for use, each containing a combination of antiretroviral drugs:

Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC)

• This combination, often known by the brand name Truvada, was the first PrEP medication approved.


• It is effective for all individuals at risk of HIV through sexual activity or injection drug use.


• Generic versions are widely available, making it more accessible.


• Potential side effects can include kidney function changes and bone mineral density loss, which are typically mild and reversible upon discontinuation.

Tenofovir Alafenamide/Emtricitabine (TAF/FTC)

• This combination, known by the brand name Descovy, was approved later.


• It is approved for individuals at risk of HIV through sexual activity, excluding receptive vaginal sex.


• TAF is a newer formulation of tenofovir that is associated with less impact on kidney function and bone mineral density compared to TDF.


• Like TDF/FTC, generic versions are also becoming available.

Both TDF/FTC and TAF/FTC are taken once daily. Consistency in taking the medication is key to its effectiveness.

3. Injectable PrEP: A Long-Acting Option

For individuals who prefer an alternative to daily pills, an injectable PrEP option is available:

Cabotegravir Extended-Release Injectable Suspension

• Marketed under the brand name Apretude, this medication is given as an intramuscular injection.


• Initially, two doses are given one month apart, followed by one injection every two months thereafter.


• This long-acting option can be a convenient choice for individuals who may struggle with daily pill adherence.


• Cabotegravir is approved for individuals at risk of HIV through sexual activity.


• Common side effects include injection site reactions (pain, tenderness, swelling), fever, fatigue, and headache.

Before starting injectable PrEP, a lead-in period with oral cabotegravir may be recommended to assess tolerability, though this is not always mandatory.

4. Key Differences and Considerations

Choosing between oral and injectable PrEP involves considering several factors:

• Dosing Frequency: Oral PrEP requires daily adherence, while injectable PrEP is administered every two months.


• Administration: Oral PrEP is self-administered as a pill, whereas injectable PrEP requires regular visits to a healthcare provider for the injection.


• Side Effect Profiles: While both are generally well-tolerated, their specific side effect profiles differ, particularly regarding kidney and bone health for oral options and injection site reactions for the injectable.


• Approved Use: TDF/FTC is approved for all at-risk populations. TAF/FTC and cabotegravir are currently approved for individuals at risk through sexual activity (with TAF/FTC excluding receptive vaginal sex).

5. Important Steps Before Starting PrEP

Regardless of the medication option chosen, several critical steps must be completed before initiating PrEP:

• HIV Negative Status Confirmation: An individual must be confirmed HIV-negative immediately before starting PrEP and at regular intervals while on PrEP. Taking PrEP when HIV-positive can lead to drug resistance.


• Kidney Function Testing: Especially important for oral PrEP, kidney function should be assessed before and during treatment.


• Hepatitis B Status: PrEP medications also have activity against Hepatitis B. Individuals with Hepatitis B who stop PrEP may experience a flare-up of their Hepatitis B infection.


• Discussion with a Healthcare Provider: A thorough discussion with a qualified healthcare provider is essential to determine the most suitable PrEP option based on individual risk factors, health status, and lifestyle.

6. Accessing PrEP and Ongoing Monitoring

Once a PrEP medication option is chosen, access typically involves a prescription from a healthcare provider. Many programs and insurance plans offer assistance with the cost of PrEP. Ongoing monitoring is vital and includes regular follow-up appointments, HIV testing, STI screening, and assessment of kidney function for oral PrEP. Adherence to the prescribed regimen and attending all follow-up appointments are crucial for PrEP's continued effectiveness.

Summary

PrEP offers highly effective protection against HIV acquisition and is available in both daily oral pill and long-acting injectable forms. Oral options include TDF/FTC (Truvada and generics) and TAF/FTC (Descovy and generics), differing in their approved uses and potential impact on kidney and bone health. The injectable option, cabotegravir (Apretude), offers bi-monthly administration. Selecting the most appropriate PrEP medication involves careful consideration of individual risk factors, lifestyle, and potential side effects, always in consultation with a healthcare provider. Regular medical follow-ups and consistent adherence are essential for maximizing PrEP's protective benefits.